Shattuck Labs, Inc. (NASDAQ: STTK) announced plans to evaluate its drug candidate SL-325 in a Phase 2 clinical trial targeting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE